Literature DB >> 20180057

[Problems, objective, and substance of early detection of prostate cancer].

C Börgermann1, H Loertzer, P Hammerer, P Fornara, M Graefen, H Rübben.   

Abstract

The current S3 guideline for early detection of prostate cancer initiates a change to the paradigm in early detection from the detection of all prostate cancers to the identification of aggressive prostate cancers. Early detection is performed annually and starts at the age of 40 years; it should be terminated at a life expectancy of less then 10 years. The choice of the frequency of early detection should be risk adapted. The digital rectal examination is supplemented by determination of PSA. Previous to the first PSA test the patient has to be informed concerning possible consequences such as biopsy recommendation and treatment options. A threshold of 4 ng/ml is defined as an indication for prostate biopsy for the first administration. In the following early detections the PSA velocity should be considered. Today imaging methods do not play a major role in early detection of prostate cancer. Early detection identifies many latent prostate cancers and patients may receive overtreatment. The recent S3 guideline for early detection is discussed against this background on the basis of the recent literature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180057     DOI: 10.1007/s00120-010-2234-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  36 in total

1.  Prostate-specific antigen dynamics and prostate cancer diagnosis.

Authors:  Riccardo Bartoletti
Journal:  Eur Urol       Date:  2009-08-04       Impact factor: 20.096

2.  Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer?

Authors:  Frank Oberpenning; Stefan Hetzel; Christoph Weining; Burkhard Brandt; Gabriela De Angelis; Achim Heinecke; Michael Lein; Paolo Fornara; Hans-Peter Schmid; Lothar Hertle; Axel Semjonow
Journal:  Eur Urol       Date:  2003-05       Impact factor: 20.096

3.  Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy.

Authors:  A H Horan; M McGehee
Journal:  BJU Int       Date:  2000-06       Impact factor: 5.588

4.  Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.

Authors:  C V Smith; J J Bauer; R R Connelly; T Seay; C Kane; J Foley; J B Thrasher; L Kusuda; J W Moul
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

5.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

6.  Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease.

Authors:  H B Carter; J I Epstein; A W Partin
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

7.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

8.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

Review 10.  Overdiagnosis and overtreatment of early detected prostate cancer.

Authors:  C H Bangma; S Roemeling; F H Schröder
Journal:  World J Urol       Date:  2007-02-14       Impact factor: 4.226

View more
  4 in total

Review 1.  [Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?].

Authors:  P Thelen; R-H Ringert; H Loertzer; A Strauß
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

2.  [Antiandrogen strategies in prostate cancer: reconstitution of oestrogen receptor beta].

Authors:  P Thelen; A Strauss; M Stettner; S Kaulfuss; R-H Ringert; H Loertzer
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

Review 3.  [Fusion imaging in urology: combination of MRI and TRUS for detection of prostate cancer].

Authors:  D Schilling; M Kurosch; R Mager; I Tsaur; A Haferkamp; M Röthke
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

4.  [Criteria for errors in prostate-specific antigen diagnostics].

Authors:  V Lent; F Baumbusch; B Weber
Journal:  Urologe A       Date:  2012-11       Impact factor: 0.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.